No abstract available.
Bupropion ; Sexual Behavior ; Ticlopidine

The impacts from the bupropion on the brain structures have seldom been mentioned in the literature. The bupropion is a kind of antidepressant with dual action in the norepinephrine and dopamine receptors. Here we have a case to share about the bupropion-related effects in the brain structure.
Brain* ; Bupropion* ; Depression* ; Humans ; Norepinephrine ; Receptors, Dopamine

This review examined the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. It briefly addresses the issues about the cause of hospital visit, diagnosis, and impact of disease, specific to adults. The article focused on the evidence regarding the efficacy and tolerability of short- and long-acting stimulant medications, as well as the non-stimulant medications such as atomoxetine and bupropion in the treatment of the adult ADHD. Generally speaking, variability in diagnostic criteria, dosing parameters and response rates between the various studies were considerable. The aggregated literature shows that both the stimulants and non-stimulants had clinically significant beneficial effect on treating ADHD in adults. Special attention is given to the pharmacological treatment for patients with adult ADHD and various comorbidities. In summary, medications are effective and combined medication and psychosocial treatment is the most beneficial treatment option for most adult patients with ADHD.
Adult ; Bupropion ; Comorbidity ; Humans ; Propylamines ; Atomoxetine Hydrochloride

This review examined the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. It briefly addresses the issues about the cause of hospital visit, diagnosis, and impact of disease, specific to adults. The article focused on the evidence regarding the efficacy and tolerability of short- and long-acting stimulant medications, as well as the non-stimulant medications such as atomoxetine and bupropion in the treatment of the adult ADHD. Generally speaking, variability in diagnostic criteria, dosing parameters and response rates between the various studies were considerable. The aggregated literature shows that both the stimulants and non-stimulants had clinically significant beneficial effect on treating ADHD in adults. Special attention is given to the pharmacological treatment for patients with adult ADHD and various comorbidities. In summary, medications are effective and combined medication and psychosocial treatment is the most beneficial treatment option for most adult patients with ADHD.
Adult ; Bupropion ; Comorbidity ; Humans ; Propylamines ; Atomoxetine Hydrochloride

The prevalence of obesity and overweight is increasing in mood disorder, and it is connected to an increased cardiovascular mortality. Because of them, treatment for obesity may be an essential part of mood disorder treatment. Similar to the general population, non-pharmacological treatment such as correction of life habits should be considered first of all. If this approaches are fail, pharmacological treatment for obesity would be required as next step. Any drug for obesity is not approved officially in mood disorder. So approved drugs in general population, and drugs supported by several studies are prescribed in clinical settings. Several treatment guidelines for mood disorder and studies support that orlistat, metformin, topiramate and bupropion is effective and safe.
Bupropion ; Drug Therapy* ; Metformin ; Mood Disorders* ; Mortality ; Obesity* ; Overweight ; Prevalence

The aim of this paper is to evaluate the use of non-stimulants, including atomoxetine, bupropion and modafinil, as alternative approaches to the treatment of children with attention-deficit hyperactivity disorder. A comprehensive review of the empirically based literature regarding the efficacy and the safety of the non-stimulants was performed. There is a large and increasing body of data supporting the efficacy and the safety of non-stimulants. Although the treatment effect sizes for non-stimulants may be smaller than those for stimulants, non-stimulants alone have been shown to be effective in the treatment of attention-deficit hyperactivity disorder as well as several comorbidities. These results suggest that nonstimulants are effective in the treatment of attention-deficit hyperactivity disorder. Further studies are needed to improve our understanding of alternative pharmacological medications in the treatment of attention-deficit hyperactivity disorder.
Benzhydryl Compounds ; Bupropion ; Child ; Comorbidity ; Humans ; Propylamines ; Atomoxetine Hydrochloride

Present report describes a 46 year old male patient with a diagnosis of major depression who developed tardive dyskinesia during bupropion therapy. Our patient had no history of neuroleptic use and his laboratory and neurologic examinations were normal. He had no family history of neurologic diseases. Although bupropion induced dyskinesia has been previously reported in the literature, it is rare and our case is the first case regarding tardive dyskinesia.
Bupropion* ; Depression ; Diagnosis ; Dyskinesias ; Humans ; Male ; Movement Disorders* ; Neurologic Examination

This article discusses the mechanism of action of Wellbutrin (bupropion) and relates the drug's neuropharmacologic effects to its clinical efficacy and side effect profiles. The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. With respect to treatment of depression, these catecholaminergic effects of bupropion tended to produce more robust effects on anhedonia/positive affect. Augmenting or switching antidepressants with bupropion has become an increasingly common strategy in the treatment of resistant depression. Bupropion has been suggested for the treatment of bipolar depression , because of its efficacy and a lower risk of inducing switches to hypomania or mania. Clinically, SR formulation, side effects are infrequent and benign, would be used without a risk of seizure in dose up to 400 mg/day.
Antidepressive Agents ; Bipolar Disorder ; Bupropion* ; Depression* ; Dopamine ; Neuropharmacology ; Norepinephrine ; Seizures

Cigarette smoking is motivated primarily by a desire for nicotine. Nicotine provides direct effects such as pleasure, stimulation, and stress relief, and it also reverses the unpleasant symptoms of nicotine withdrawal. Most smokers try to quit smoking but find it difficult because of nicotine addiction. Both behavioral counseling and and pharmacotherapy increase the cessation rates, and the effects of these interventions are generally additive. Recent guidelines for smoking cessation recommend that all smokers trying to quit should be offered pharmacotherapy. Two classes of medications have been approved for smoking cessation: nicotine replacement medications and bupropion, which was originally marketed as an antidepressant drug. The choice of medications should be individualized-based on the patient's preference,tolerance of adverse effects, and smoking habits.The combination nicotine replacement therapy-a patch plus short acing formulations such as gum or troche is increasingly prescribed to patients with severe addiction. All types of smoking cessation medications, if used properly, double the smoking cessation rate compared with placebo treatment. Some data suggest that the combination and extended duration of pharmacotherapies may offer some advantages, especially in dependent smokers, but these results have been inconclusive. The optimal combinations of medications for tobacco dependence treatment are not yet determined, and few studies have evaluated the effects of more complex combinations.
Bupropion ; Counseling ; Drug Therapy ; Gingiva ; Humans ; Nicotine ; Pleasure ; Smoke* ; Smoking Cessation* ; Smoking* ; Tobacco Use Disorder

OBJECTIVE: Early maternal separation (EMS) during the development has been known to influence the alteration of behavior in adulthood. Nitric oxide (NO) may have been implicated to play a crucial role in the neurodevelopment as an intracellular and intercellular messenger. This study was designed to investigate the neurochemical mechanism of the behavioral changes resulting from EMS during the development in juvenile rats. METHODS: Experimental group consisted of subjects that were removed and weaned from the day on postnatal day 15. Control group were the litters that experienced no EMS until postnatal day 21. On postnatal day 15 and 36, the locomotor activity (LA) was measured. On postnatal day 36 the behavioral changes in the forced swimming test (FST) were also measured. Test drugs were intraperitoneally injected including MK-801 (0.5 mg/kg), N omega-nitro-L-arginine (L-NA, 20 mg/kg), paroxetine (20 mg/kg), and bupropion (150 mg/kg). RESULTS:EMS produced the decrease of LA significantly in juvenile rats (p<0.001). Both MK-801 and L-NA increased LA in experimental group (p<0.001) and control group (p<0.05). The degree of increase was higher in experimental group than in control group. However, both paroxetine and bupropion increased LA in experimental group (p<0.001, p<0.05), but not in control group. In the FST, immobility was significantly increased in experimental group compared with control group (p<0.001). The increases of immobility in experimental group were abolished after injecting MK-801, L-NA, paroxetine, and bupropion, respectively. CONCLUSION: These results indicate that EMS during the development can lead to behavioral abnormalities in juvenile rats. The underlying neurochemical mechanism of this behavioral changes may be, in part, related to the glutamatergic NMDA-NO pathway. This suggests that glutamatergic NMDA-NO pathway vulnerable to stress may predispose to depression.
Animals ; Bupropion ; Depression ; Dizocilpine Maleate ; Motor Activity ; Nitric Oxide ; Nitroarginine ; Paroxetine ; Rats ; Swimming